Unrestrained glycogen synthase kinase-3β activity leads to activated T cell death and can be inhibited by natural adjuvant

Journal of Immunology

Volumn 178, Issue 10, 2007, Pages 6083-6091

  Sengupta, Sadhak ^a   Jayaraman, Padmini ^a   Chilton, Paula M ^a   Casella, Carolyn R ^a   Mitchell, Thomas C ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; LIPOPOLYSACCHARIDE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEMALE; HOMEOSTASIS; IMMUNE SYSTEM; IN VIVO CULTURE; LYMPHOCYTE CLONE; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 34248152731     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.10.6083     Document Type: Article

References (58)

1. Sepulveda, H., A. Cerwenka, T. Morgan, and R. W. Dutton. 1999. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation. J. Immunol. 163: 1133-1142.
2. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155: 1032-1036.
3. Kondrack, R. M., J. Harbertson, J. T. Tan, M. E. McBreen, C. D. Surh, and L. M. Bradley. 2003. Interleukin 7 regulates the survival and generation of memory CD4 cells. J. Exp. Med. 198: 1797-1806.
4. Linton, P. J., B. Bautista, E. Biederman, E. S. Bradley, J. Harbertson, R. M. Kondrack, R. C. Padrick, and L. M. Bradley. 2003. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197: 875-883.
5. Akbar, A. N., and M. Salmon. 1997. Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Immunol. Today 18: 72-76.
6. Vella, A. T., S. Dow, T. A. Potter, J. Kappler, and P. Marrack. 1998. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95: 3810-3815.
7. Hildeman, D. A., Y. Zhu, T. C. Mitchell, J. Kappler, and P. Marrack. 2002. Molecular mechanisms of activated T cell death in vivo. Curr. Opin. Immunol. 14: 354-359.
8. Hildeman, D. A., Y. Zhu, T. C. Mitchell, P. Bouillet, A. Strasser, J. Kappler, and P. Marrack. 2002. Activated T cell death in vivo mediated by proapoptotic Bcl-2 family member Bim. Immunity 16: 759-767.
9. Vella, A. T., J. E. McCormack, P. S. Linsley, J. W. Kappler, and P. Marrack. 1995. Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity 2: 261-270.
10. Sengupta, S., P. M. Chilton, and T. C. Mitchell. 2005. Adjuvant-induced survival signaling in clonally expanded T cells is associated with transient increases in pAkt levels and sustained uptake of glucose. Immunobiology 210: 647-659.
11. Li-Weber, M., and P. H. Krammer. 2003. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin. Immunol. 15: 145-157.
12. + T cells. J. Immunol. 163: 1817-1826.
13. Tucek-Szabo, C. L., S. Andjelic, E. Lacy, K. B. Elkon, and J. Nikolic-Zugic. 1996. Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis: activation-induced death can occur without Fas receptor. J. Immunol. 156: 192-200.
14. Marrack, P., and J. Kappler. 2004. Control of T cell viability. Annu. Rev. Immunol. 22: 765-787.
15. Lohman, B. L., E. S. Razvi, and R. M. Welsh. 1996. T-lymphocyte downregulation after acute viral infection is not dependent on CD95 (Fas) receptor-ligand interactions. J. Virol. 70: 8199-8203.
16. Pellegrini, M., G. Belz, P. Bouillet, and A. Strasser. 2003. Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim. Proc. Natl. Acad. Sci. USA 100: 14175-14180.
17. Van Houten, N., and R. C. Budd. 1992. Accelerated programmed cell death of MRL-lpr/lpr T lymphocytes. J. Immunol. 149: 2513-2517.
18. Vella, A. T., T. Mitchell, B. Groth, P. S. Linsley, J. M. Green, C. B. Thompson, J. W. Kappler, and P. Marrack. 1997. CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J. Immunol. 158: 4714-4720.
19. Medzhitov, R., and C. Janeway, Jr. 2000. The Toll receptor family and microbial recognition. Trends Microbiol. 8: 452-456.
20. Mitchell, T. C., D. Hildeman, R. M. Kedl, T. K. Teague, B. C. Schaefer, J. White, Y. Zhu, J. Kappler, and P. Marrack. 2001. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat. Immunol. 2: 397-402.
21. L, costimulation, or antioxidants with adjuvant-induced T cell survival. Ann. NY Acad. Sci. 975: 114-131.
22. Okkenhaug, K., A. Bilancio, J. L. Emery, and B. Vanhaesebroeck. 2004. Phosphoinositide 3-kinase in T cell activation and survival. Biochem. Soc. Trans. 32: 332-335.
23. Hetman, M., J. E. Cavanaugh, D. Kimelman, and Z. Xia. 2000. Role of glycogen synthase kinase-3β in neuronal apoptosis induced by trophic withdrawal. J. Neurosci. 20: 2567-2574.
24. Elyaman, W., F. Terro, N. S. Wong, and J. Hugon. 2002. In vivo activation and nuclear translocation of phosphorylated glycogen synthase kinase-3β in neuronal apoptosis: links to τ phosphorylation. Eur J. Neurosci. 15: 651-660.
25. Sutherland, C., I. A. Leighton, and P. Cohen. 1993. Inactivation of glycogen synthase kinase-3β by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296(Pt. 1): 15-19.
26. Cross, D. A., D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
27. Embi, N., D. B. Rylatt, and P. Cohen. 1980. Glycogen synthase kinase-3 from rabbit skeletal muscle: separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J. Biochem. 107: 519-527.
28. Manoukian, A. S., and J. R. Woodgett. 2002. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv. Cancer Res. 84: 203-229.
29. Meijer, L., M. Flajolet, and P. Greengard. 2004. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 25: 471-480.
30. Woodgett, J. R. 1994. Regulation and functions of the glycogen synthase kinase-3 subfamily. Semin. Cancer Biol. 5: 269-275.
31. Bijur, G. N., and R. S. Jope. 2000. Opposing actions of phosphatidylinositol 3-kinase and glycogen synthase kinase-3β in the regulation of HSF-1 activity. J. Neurochem. 75: 2401-2408.
32. Neal, J. W., and N. A. Clipstone. 2001. Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. J. Biol. Chem. 276: 3666-3673.
33. Watcharasit, P., G. N. Bijur, L. Song, J. Zhu, X. Chen, and R. S. Jope. 2003. Glycogen synthase kinase-3β (GSK3β) binds to and promotes the actions of p53. J. Biol. Chem. 278: 48872-48879.
34. Diehl, J. A., M. Cheng, M. F. Roussel, and C. J. Sherr. 1998. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12: 3499-3511.
35. Jope, R. S., and G. V. Johnson. 2004. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29: 95-102.
36. Steinbrecher, K. A., W. Wilson III, P. C. Cogswell, and A. S. Baldwin. 2005. Glycogen synthase kinase 3β functions to specify gene-specific, NF-κB-dependent transcription. Mol. Cell. Biol. 25: 8444-8455.
37. Welsh, G. I., S. Miyamoto, N. T. Price, B. Safer, and C. G. Proud. 1996. T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3. J. Biol. Chem. 271: 11410-11413.
38. Christian, S. L., P. V. Sims, and M. R. Gold. 2002. The B cell antigen receptor regulates the transcriptional activator β-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3. J. Immunol. 169: 758-769.
39. Martin, M., K. Rehani, R. S. Jope, and S. M. Michalek. 2005. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6: 777-784.
40. Ohteki, T., M. Parsons, A. Zakarian, R. G. Jones, L. T. Nguyen, J. R. Woodgett, and P. S. Ohashi. 2000. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J. Exp. Med. 192: 99-104.
41. Song, J., S. Salek-Ardakani, P. R. Rogers, M. Cheng, P. L. Van, and M. Croft. 2004. The costimulation-regulated duration of PKB activation controls T cell longevity. Nat. Immunol. 5: 150-158.
42. McCormack, J. E., J. E. Callahan, J. Kappler, and P. C. Marrack. 1993. Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J. Immunol. 150: 3785-3792.
43. Mitchell, T., J. Kappler, and P. Marrack. 1999. Bystander virus infection prolongs activated T cell survival. J. Immunol. 162: 4527-4535.
44. Mitchell, T. C., B. S. Thompson, J. O. Trent, and C. R. Casella. 2002. A short domain within Bcl-3 is responsible for its lymphocyte survival activity. Ann. NY Acad. Sci. 975: 132-147.
45. Pap, M., and G. M. Cooper. 1998. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 273: 19929-19932.
46. -ΔΔCτ method. Methods 25: 402-408.
47. Coghlan, M. P., A. A. Culbert, D. A. Cross, S. L. Corcoran, J. W. Yates, N. J. Pearce, O. L. Rausch, G. J. Murphy, P. S. Carter, C. L. Roxbee, et al. 2000. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7: 793-803.
48. Frame, S., P. Cohen, and R. M. Biondi. 2001. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell. 7: 1321-1327.
49. Dajani, R., E. Fraser, S. M. Roe, N. Young, V. Good, T. C. Dale, and L. H. Pearl. 2001. Crystal structure of glycogen synthase kinase 3β: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105: 721-732.
50. Carbone, F. R., M. W. Moore, J. M. Sheil, and M. J. Bevan. 1988. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J. Exp. Med. 167: 1767-1779.
51. Ikeda, S., S. Kishida, H. Yamamoto, H. Murai, S. Koyama, and A. Kikuchi. 1998. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β and β-catenin and promotes GSK-3β-dependent phosphorylation of β-catenin. EMBO J. 17: 1371-1384.
52. Maurer, U., C. Charvet, A. S. Wagman, E. Dejardin, and D. R. Green. 2006. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 21: 749-760.
53. Appleman, L. J., A. A. Van Puijenbroek, K. M. Shu, L. M. Nadler, and V. A. Boussiotis. 2002. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 168: 2729-2736.
54. + T cells and enables CpG oligodeoxynucleotide- mediated costimulation. Immunity 25: 783-793.
55. Staal, F. J., J. Meeldijk, P. Moerer, P. Jay, B. C. van de Weerdt, S. Vainio, G. P. Nolan, and H. Clevers. 2001. Wnt signaling is required for thymocyte development and activates Tcf-1 mediated transcription. Eur. J. Immunol. 31: 285-293.
56. + thymocyte survival. Nat. Immunol. 2: 691-697.
57. Xu, Y., D. Banerjee, J. Huelsken, W. Birchmeier, and J. M. Sen. 2003. Deletion of β-catenin impairs T cell development. Nat. Immunol. 4: 1177-1182.
58. Opferman, J. T., A. Letai, C. Beard, M. D. Sorcinelli, C. C. Ong, and S. J. Korsmeyer. 2003. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426: 671-676.